Accord BioPharma Launches Cost-Effective IMULDOSA Biosimilar
Accord BioPharma, the specialty division of Intas Pharmaceuticals, has officially launched IMULDOSA® (ustekinumab-srlf), a new biosimilar that offers a more affordable alternative to STELARA® (ustekinumab). This significant launch is poised to provide patients with greater access to crucial biologic therapies that target chronic inflammatory diseases.
Providing Essential Support for Patients
With the launch of IMULDOSA, Accord BioPharma is not just introducing another product to the market but is also expanding the support services available to patients navigating chronic conditions. Many patients suffer from debilitating diseases such as plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. These conditions can dramatically impact their quality of life. Hence, Accord BioPharma is focused on providing tools and resources, along with cost-effective medication options that enhance patient experiences and outcomes.
Strategic Pricing to Increase Patient Access
Accord BioPharma is setting the standard with IMULDOSA by pricing it at the lowest wholesaler acquisition cost (WAC) compared to its branded competitors, offering a remarkable 92% reduction compared to STELARA. This effort exemplifies the company's commitment to making advanced biologic therapy financially accessible. The other formulation of IMULDOSA also features a competitive discount of 33% to maximize affordability.
Innovative Patient Support Programs
In conjunction with the commercial launch, Accord has initiated a $0 co-pay program for eligible patients. This program is designed to alleviate financial barriers, thereby allowing more individuals with chronic inflammatory conditions to benefit from high-quality medical care. Accord’s approach reflects its dedication to ensuring that economic factors do not hinder access to critical medications.
Accord BioPharma's Vision for Immunology
IMULDOSA marks the third biosimilar introduced by Accord BioPharma, which is laying the groundwork for a comprehensive immunology portfolio. This strategic expansion demonstrates the company's responsiveness to the essential needs within immune-mediated conditions. The feedback and insights from patient advisory committees have been invaluable in shaping patient-centric materials related to the product and its administration.
Commitment to Quality and Efficacy
Accord BioPharma emphasizes that IMULDOSA has been demonstrated to be highly similar to its reference product, STELARA, ensuring patients can expect comparable efficacy without clinically significant differences. The FDA-approved indications are aligned with STELARA, ensuring that the patient population previously treated with the reference product can transition safely to using IMULDOSA without loss of treatment effectiveness.
Rich Portfolio and Future Development Plans
The launch of IMULDOSA adds to Accord BioPharma's growing portfolio that includes UDENYCA® (pegfilgrastim-cbqv), HERCESSI™ (trastuzumab-strf), and CAMCEVI® (leuprolide). Accord is also actively developing additional biosimilars and has submitted Biologics License Applications to the FDA for multiple candidates. The collaborative initiative with Bio-Thera Solutions to introduce BAT2506, a biosimilar to Simponi® (golimumab), further enhances Accord’s offerings in the U.S. market.
Conclusion
Accord BioPharma is dedicated to addressing the needs of patients through innovative and accessible healthcare solutions. The introduction of IMULDOSA at the most competitive price point among branded ustekinumab biosimilars underscores the company’s mission to transform patient care and support. The future looks promising as Accord continues to innovate and expand its biosimilar portfolio to enhance patient outcomes across various therapeutic areas.
Frequently Asked Questions
What is IMULDOSA and what conditions does it treat?
IMULDOSA is a biosimilar to STELARA used for treating moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
How does Accord BioPharma ensure patient access to IMULDOSA?
Accord BioPharma has implemented a $0 co-pay program for eligible patients and priced IMULDOSA at the lowest WAC among branded ustekinumab biosimilars.
Can IMULDOSA be used in place of STELARA?
Yes, IMULDOSA has been proven to be highly similar to STELARA with FDA-approved indications making it a viable alternative.
What support resources does Accord provide for IMULDOSA patients?
Accord offers patient support materials and has engaged patient advisory boards to ensure resources are relevant and helpful.
What is the company’s commitment to biosimilars?
Accord BioPharma aims to provide affordable and effective biologic therapies, believing that biosimilars can significantly enhance patient access to necessary treatments.
